Based on stakeholder comments, the FDA has made changes to the online questionnaire it plans to use to collect information from 1,000 consumers about adverse events they have experienced and believe were caused by allergens in cosmetic products. The agency remains confident that the pilot study will provide useful insight into cosmetic allergy prevalence in the US.
The US Food and Drug Administration is moving forward with a web-based survey that it believes will shed light on the prevalence of adverse reactions to cosmetic products attributed to allergens.
Industry stakeholders were skeptical in comments submitted to the FDA, following the agency’s notice of the pilot study,